AKAM
21
-6
TRV
31
-18
IRM
23
-11
KMX
48
-4
EQR
31
-13
MAR
20
-7
EXR
19
-21
UNM
49
-14
AMZN
38
-3
REGN
23
-7
AIV
30
-7
AME
35
-4
PG
51
-17
AAP
18
-3
AVGO
8
-2
NI
43
-20
PRGO
31
-6
URBN
43
-4
AIZ
52
-12
BWA
21
-7
AKAM
21
-6
TRV
31
-18
IRM
23
-11
KMX
48
-4
EQR
31
-13
MAR
20
-7
EXR
19
-21
UNM
49
-14
AMZN
38
-3
REGN
23
-7
AIV
30
-7
AME
35
-4
PG
51
-17
AAP
18
-3
AVGO
8
-2
NI
43
-20
PRGO
31
-6
URBN
43
-4
AIZ
52
-12
BWA
21
-7
Financhill
Back

Phathom Pharmaceuticals 10K Form

Sell
11

PHAT
Phathom Pharmaceuticals

Last Price:
$4.87
Seasonality Move:
17.73%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PHAT News And Ratings

See the #1 stock for the next 7 days that we like better than PHAT

PHAT Financial Statistics

Sales & Book Value

Annual Sales: $55.3M
Cash Flow: $-63.5M
Price / Cash Flow: 0
Annual Sales: $-3.70
Price / Book: 0

Profitability

EPS (TTM): -5.35000
Net Income (TTM): $-334.3M
Gross Margin: $47.3M
Return on Equity: 0%
Return on Assets: -90.11%

Phathom Pharmaceuticals Earnings Forecast

Key Phathom Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 3 years for PHAT is 85.57%.
  • The Selling, General & Administrative Expenses for PHAT have been equal to 526.07% of Gross Profit Margin.
  • The Research & Development expenses have been 61.68% of Revenue.
  • The Net Earning history of PHAT is -605.09% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 2 years.

Phathom Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PHAT
CUSIP: 71722W
Website: phathompharma.com

Debt

Debt-to-Equity Ratio: -0.79
Current Ratio: 4.2
Quick Ratio: 3.92

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PHAT Technical Analysis vs Fundamental Analysis

Sell
11
Phathom Pharmaceuticals (PHAT) is a Sell

Is Phathom Pharmaceuticals a Buy or a Sell?